Welcome to Santorini Conferences series Association (SCs)

Lorem ipsum proin gravida nibh vel veali quetean sollic lorem quis bibendum nibh vel velit.

Evently

Stay Connected & Follow us

Simply enter your keyword and we will help you find what you need.

What are you looking for?

Good things happen when you narrow your focus
Welcome to Conference

Write us on info@santorniconference.org

Follow Us

  /  Dr. Mark William Ruddock                                                       

Dr. Mark William Ruddock                                                       

Personal Details 

Name:  Mark William Ruddock                                                       
 

Postal Address at Institution: 

 

Randox Laboratories Ltd 

Clinical Studies Group 

Randox Science Park 

30 Randalstown Road 

Antrim 

County Antrim BT41 4FL 

Northern Ireland 

United Kingdom 

 

Academic Qualifications, Relevant Training and Courses 

From  To  Institution/Course provider  Qualification obtained (degree level and subject e.g. MSc Biology)/ relevant training or course attended  
1998  2000  Harvard University, Boston, US  Research Fellow in Medicine 
1995  1998  Ulster University, Belfast, UK  PhD – Oncology 
1992  1995  Ulster University, Belfast, UK  BSc (Hons) – Biochemistry 

Employment History 

From  To  Position Title  Institution  Location 
2020  Present  Occasional Lecturer  Queens University Belfast  Belfast, NI, UK 
2001  Present  Clinical Studies and Development Manager  Randox Laboratories Ltd  Crumlin, Antrim, NI, UK 
2000  2001  Lecturer  Ulster University Belfast  Belfast, NI, UK 
1998  2000  Research Fellow in Medicine  Harvard Medical School  Boston, MA, US 

Recent Publications 2022 – 2023 

  1. Watt J, Kurth MJ, Reid CN, Lamont JV, Fitzgerald P, Ruddock MW. Non-alcoholic fatty liver disease-A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease. Front Physiol. 2022 Dec 15; 13:963513. doi: 10.3389/fphys.2022.963513. PMID: 36589452; PMCID: PMC9801299. 
  1. Duggan B, O’Rourke D, Anderson N, Reid CN, Watt J, O’Kane H, Boyd R, Curry D, Evans M, Stevenson M, Kurth MJ, Lamont JV, Fitzgerald P, Ruddock MW. Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific. Front Oncol. 2022 Sep 23; 12:1009014. doi: 10.3389/fonc.2022.1009014. PMID: 36212463; PMCID: PMC9539269. 
  1. Awuah A, Moore JS, Nesbit MA, Ruddock MW, Brennan PF, Mailey JA, McNeil AJ, Jing M, Finlay DD, Trucco E, Kurth MJ, Watt J, Lamont JV, Fitzgerald P, Spence MS, McLaughlin JAD, Moore TCB. A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers. Sci Rep. 2022 Apr 21;12(1):6545. doi: 10.1038/s41598-022-10491-7. PMID: 35449196; PMCID: PMC9023476. 
  1. Tonry CL, Evans RM, Ruddock MW, Duggan B, McCloskey O, Maxwell AP, O’Rourke D, Boyd RE, Watt J, Reid CN, Curry DJ, Stevenson M, Young MK, Jamison CS, Gallagher J, Fitzgerald SP, Lamont J, Watson CJ. Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuria. Diabetes Metab Res Rev. 2022 Sep;38(6): e3546. doi: 10.1002/dmrr.3546. Epub 2022 May 22. PMID: 35578575; PMCID: PMC9542076. 
  1. Harkin C, Cobice D, Brockbank S, Bolton S, Johnston F, Strzelecka A, Watt J, Kurth MJ, Lamont JV, Fitzgerald P, Moore T, Ruddock MW. Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients. Front Endocrinol (Lausanne). 2022 Jun 29; 13:887237. doi: 10.3389/fendo.2022.887237. PMID: 35846341; PMCID: PMC9276980. 
  1. McNally CJ, Watt J, Kurth MJ, Lamont JV, Moore T, Fitzgerald P, Pandha H, McKenna DJ, Ruddock MW. A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer. Front Oncol. 2022 May 19; 12:837127. doi: 10.3389/fonc.2022.837127. PMID: 35664747; PMCID: PMC9161691. 
  1. Ruddock MW, Watt J, Kurth MJ, et al. (2022) Post-Traumatic Stress Disorder: Identifying Potential Differences in Participant Response to CAPS-5 Life Events Checklist Questionnaire Based on Gender. J Depress Anxiety Disord. 4(1):127-131. 
  1. Maguire, D., Armour, C., Lagdon, S., Ruddock, M., Moore, T., & Milanak, M. (2022). Improving sleep in a population at high risk of trauma: A pilot study examining self-reported sleep, psychological symptomology and actigraphy measured night-time sleep. European Psychiatry, 65(S1), S809-S810. doi: 10.1192/j.eurpsy.2022.2094. 
  1. Harkin C, Cobice D, Watt J, Kurth MJ, Brockbank S, Bolton S, Johnston F, Strzelecka A, Lamont JV, Moore T, Fitzgerald P and Ruddock MW (2022) Analysis of reactive aldehydes in urine and plasma of type-2 diabetes mellitus patients through liquid chromatography-mass spectrometry: Reactive aldehydes as potential markers of diabetic nephropathy. Front. Nutr. 9:997015. doi: 10.3389/fnut.2022.997015. 
  1. Harkin, C., Smith, K.W., MacKay, C.L., Moore, T., Brockbank, S., Ruddock, M., Cobice, F. Spatial localization of β-unsaturated aldehyde markers in murine diabetic kidney tissue by mass spectrometry imaging. Anal Bioanal Chem. 414, 6657–6670 (2022).  
  1. Ruddock MW, Watt J, Kurth MJ, et al. (2023) Sleep Disturbances and Chronic Pain as Potential Indicators for Therapeutic Intervention in Subjects with Post-Traumatic Stress Disorder. J Depress Anxiety Disord. 5(1):141-150. 
  1. Ruddock MW et al. Stratifying risk of bladder cancer in patients who present with haematuria using biomarkers and machine self-semantic learning. Journal of Medical Internet Research (2023) (in press). 

Additional Information 

MSc and PhD Industrial Supervisor for Ulster University Belfast and Queens University Belfast; Lecturer in Biomarker Discovery and Cardiovascular Disease for Queens University (BSc and MSc course)